Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Graphite Bio, Inc.

Graphite Bio is a clinical-stage, next-generation gene editing company driven to discover and develop cures for a wide range of serious and life-threatening diseases. The company is pioneering a precision gene editing approach that has the potential to transform human health by achieving one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s UltraHDR™ gene editing platform takes CRISPR beyond cutting and harnesses the power of high-efficiency precision DNA repair, also known as homology-directed repair (HDR), to precisely correct genetic mutations, replace entire disease-causing genes with functional genes or insert new genes into predetermined, safe locations. Additionally, the company is advancing the development of novel conditioning regimens to help bring curative therapies to more patients. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.

See our Community Guidelines at bit.ly/3c5Pztz. 

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-109K -	-68.37M 62,627.52%	-70.76M 3.49%	-101.05M 42.81%	-124.65M 23.35%
depreciation and amortization		121K -	734K 506.61%	2.35M 220.44%	2.41M 2.34%
deferred income tax					2.36M -
stock based compensation		177K -	7.87M 4,346.89%	13.53M 71.95%	10.57M 21.87%
change in working capital	10K -	1.71M 16,990%	-2.50M 246.17%	-7.21M 188.55%	-39.22M 444.16%
accounts receivables			-14K -	-14K 0%
inventory			14K -
accounts payables	-12K -	594K 5,050%	1.82M 207.24%	194K 89.37%	-2.36M 1,315.46%
other working capital	22K -	1.11M 4,968.18%	-4.32M 487.71%	-7.39M 70.90%	-36.87M 398.98%
other non cash items	80K -	57.65M 71,956.25%	11.80M 79.53%	4.39M 62.77%	58.53M 1,232.00%
net cash provided by operating activities	-19K -	-8.72M 45,800%	-52.85M 506.03%	-87.98M 66.46%	-90.01M 2.30%
investments in property plant and equipment		-1.54M -	-5.74M 271.52%	-6.59M 14.88%	-10.86M 64.63%
acquisitions net				235.27K -	1.90M 709.29%
purchases of investments				-405.52M -	-28.13M 93.06%
sales maturities of investments				170.25M -	263.43M 54.73%
other investing activites				-235.27K -
net cash used for investing activites		-1.54M -	-5.74M 271.52%	-241.86M 4,113.64%	226.35M 193.58%
debt repayment
common stock issued		30.08M -	251.32M 735.60%	20K 99.99%	257K 1,185%
common stock repurchased				-79K -	-67K 15.19%
dividends paid
other financing activites			166.14M -	656K 99.61%
net cash used provided by financing activities		30.08M -	417.47M 1,287.99%	597K 99.86%	190K 68.17%
effect of forex changes on cash					1.60M -
net change in cash	-19K -	19.81M 104,368.42%	358.88M 1,711.49%	-329.25M 191.74%	138.13M 141.95%
cash at beginning of period	25K -	6K 76%	19.82M 330,183.33%	378.69M 1,810.95%	47.73M 87.40%
cash at end of period	6K -	19.82M 330,183.33%	378.69M 1,810.95%	49.45M 86.94%	185.86M 275.89%
operating cash flow	-19K -	-8.72M 45,800%	-52.85M 506.03%	-87.98M 66.46%	-90.01M 2.30%
capital expenditure		-1.54M -	-5.74M 271.52%	-6.59M 14.88%	-10.86M 64.63%
free cash flow	-19K -	-10.27M 53,931.58%	-58.59M 470.74%	-94.57M 61.41%	-100.86M 6.65%

COM:GRAPHITEBIO

Graphite Bio, Inc.

Last Close

3.27

21/03 20:00

Market Cap

185.19M

Beta: -

Volume Today

299.41K

Avg: -

Preview